Clinical Trials Logo

Rhabdomyosarcomas clinical trials

View clinical trials related to Rhabdomyosarcomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT00180947 Recruiting - Clinical trials for Neoplasms, Connective and Soft Tissue

Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse

Start date: June 2003
Phase: Phase 2
Study type: Interventional

This is a phase II study to determine the antitumor activity of Vinorelbine and Cyclofosfamide association among patients with refractory tumours or in relapse with rhabdomyosarcomas and other soft tissue tumours, Ewing tumours, osteosarcomas, neuroblastomas or medulloblastomas.

NCT ID: NCT00132158 Completed - Glioblastoma Clinical Trials

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

Start date: September 2005
Phase: Phase 1
Study type: Interventional

The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects. Studies performed in the laboratory have shown that ZD1839 helps make available the orally administered irinotecan. In this study the intravenous (given into the vein) formula of irinotecan will be given orally on days 1-5 and days 8-12. The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12. Each course of treatment will consist of 21 days. The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration. All other doses and subsequent courses will consist of an orally administered dose.